LZLei Zhang

Lei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lei Zhang has a total of 145 co-authors. Here are the top co-authors by number of shared publications:

  • Ao Gong

    Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250012, PR China; Second Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250012, PR China

    6 shared publications
  • Xiaojie Ma

    College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China

    6 shared publications
  • Changjun Chen

    Department of Orthopaedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, People’s Republic of China

    5 shared publications
  • Yu Fu

    Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China

    5 shared publications
  • Lin-Song Teng

    Second Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, 250001, China

    4 shared publications
  • Caiwei Wang

    Key Laboratory of Infection Immunity and Disease Intervention of Shandong Province, and Key Laboratory for Experimental Teratology of the Chinese Ministry of Education, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, China

    3 shared publications

Latest Publications

  • Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models

    by Wenyu Fu, Ronghan Liu, Jin Wo, Xin Liu, Shuya Wang, Wenhao Song, Haoran Zhu, Yazhou Cui, Yuehong Chen, Chao Wang, et al.

    Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.

  • Open Access

    Microenvironment‐Responsive Biomimetic Hydrogels Delivering Cistanche Deserticola‐Derived Nanovesicles for Intervertebral Disc Degeneration

    by Ning Xu, Xiaoyu Cai, Xiaofu Tang, Weidong Liang, Linsong Teng, Yudong Jing, Haifeng Hu, Yuhao Duan, Mingjie Kuang, Lei Zhang, et al.

    Intervertebral disc degeneration (IVDD) is driven by persistent oxidative stress and tissue acidosis, accelerating nucleus pulposus cell (NPC) senescence and extracellular matrix (ECM) degradation. While plant‐derived nanovesicles (PDNVs) hold therapeutic promise, rapid clearance and mechanical leakage constrain their translation. Here, natural nanovesicles from Cistanche deserticola (CDNVs) were incorporated into an injectable, microenvironment‐responsive hydrogel (HAPOCS@CDNVs) for localized, sustained delivery. Dynamic Schiff base and phenylboronate ester crosslinks provide biomechanical buffering, scavenge reactive oxygen species (ROS), and trigger on‐demand CDNV release under acidic and oxidative conditions. Mechanistically, CDNVs alleviate oxidative stress, support mitochondrial function, and inhibit NF‐κB activation, thereby suppressing the senescence‐associated secretory phenotype (SASP) and preserving ECM homeostasis. In a rat IVDD model, a single intradiscal injection of HAPOCS@CDNVs sustained disc height, preserved tissue hydration, and retarded degeneration over 8 weeks. This platform provides a promising, minimally invasive strategy for disc repair.

  • Repurposing the hERG activator NS-1643 as a ferroptosis-targeting therapeutic against doxorubicin cardiotoxicity

    by Xie-Huang Sheng, Lin-Song Teng, Xin-Hui Wang, Li-Qi Jiang, Xue-Cheng Sun, Jin-Long Mao, Lei Zhang

  • Open Access

    Histone demethylase KDM4B epigenetically controls NLRP3 expression to enhance inflammatory responses

    by Li Tong, Hui Song, Yuan Gao, Danhui Qin, Caiwei Wang, Qi Li, Yue Fu, Chunyuan Zhao, Zhendong Ying, Dailing Chen, et al.

    NLRP3 inflammasome, the archetypical molecular driver of inflammation, plays crucial roles in host defense and maintaining cellular homeostasis. Demethylation of histone 3 lysine 9 trimethylation (H3K9me3, the repressive mark for euchromatic genes) is essential for activating gene transcription. However, whether H3K9 demethylation is required for the induction of proinflammatory cytokines remains largely unknown. Here, we show that histone demethylase lysine-specific demethylase 4B (KDM4B) mediates H3K9me3 demethylation at the Nlrp3 promoter to induce NLRP3 expression, thereby selectively enhancing NLRP3 inflammasome activation without affecting NF-κB activation. Concordantly, both Kdm4b deficiency and the selective KDM4 inhibitor ML324 inhibit NLRP3 inflammasome activation and ameliorate NLRP3-dependent inflammatory diseases in vivo. Furthermore, high glucose level upregulates KDM4B, promoting NLRP3 inflammasome activation and IL-1β secretion, thus aggravating aberrant inflammation during viral infections. Our findings reveal the role of H3K9me3 demethylation in initiating inflammation, identify KDM4B as an epigenetic accelerator of NLRP3, and propose that modulating H3K9me3 could represent a targeted anti-inflammatory strategy.


  • Open Access

    Selenium Attenuates Dexamethasone‐Induced Osteoblast Dysfunction and Prevents Femoral Head Osteonecrosis via PI3K / AKT / GSK3β Pathway Activation

    by Sun Xuecheng, Chen Changjun, Ma Xiaojie, Li Shufeng, Zhang Lei, Xinlong Ma

    Objective: Glucocorticoid‐induced osteonecrosis of the femoral head (GC‐ONFH) represents a devastating complication of steroid therapy, primarily driven by osteoblast apoptosis and impaired osteogenesis. Although selenium (Se) is renowned for its potent bone‐protective properties, its therapeutic potential, and specific mechanisms in GC‐ONFH remain largely unexplored and thus require further investigation. Methods: To assess the therapeutic effectiveness of oral selenium supplementation in GC‐ONFH, a rat model of GC‐ONFH was utilized. The rats were randomly allocated into three groups ( n = 6 per group): (1) Control group, (2) Methylprednisolone sodium succinate (MPS) group, and (3) Se group. The intervention was carried out for 4 weeks. In vitro experiments utilized primary rat osteoblasts and MC3T3‐E1 cells to elucidate the mechanisms through which selenium mitigates dexamethasone (DEX)‐induced alterations in cell proliferation, apoptosis, and osteogenic differentiation. The assessments were conducted using micro‐CT and histomorphometry, CCK‐8 assays and flow cytometry, as well as RT–qPCR, Western blotting, and immunofluorescence. Results: Selenium supplementation effectively prevented trabecular collapse and significantly reduced the number of empty lacunae in rats with GC‐ONFH. Specifically, an optimal dose of 10 μmol Se successfully reversed the damage induced by DEX, including the restoration of cell proliferation, suppression of apoptosis, and rescue of osteogenic activity. Mechanistically, Se counteracts the DEX‐induced suppression of phosphorylated phosphatidylinositol 3‐kinase (p‐PI3K), phosphorylated protein kinase B (p‐AKT), and phosphorylated glycogen synthase kinase 3β (GSK3β) (p‐GSK3β), thereby activating the PI3K/AKT/GSK3β signaling pathway, which promotes cell proliferation, inhibits apoptosis, and enhances osteogenesis in osteoblasts. Conclusion: Selenium can activate the PI3K/AKT/GSK3β pathway, reverse DEX‐induced hypoproliferation and apoptosis, restore osteogenic capacity, prevent trabecular collapse, and attenuate GC‐ONFH in rat models. Our findings demonstrate that selenium supplementation can be regarded as a clinically applicable strategy for impeding the progression of GC‐ONFH in at‐risk patients.


  • Formoterol, a clinically approved drug, inhibits ferroptosis by suppressing lipid peroxidation and attenuates APAP-induced acute liver injury

    by Lin-Song Teng, Zhen-Dong Ying, Xiao-Han Sun, Hao-Cheng Hou, Shi-Dong Qiu, Peng Liu, Ke-Jing Li, Lei Zhang, Xie-Huang Sheng


  • Discovery of 8-hydroxy-tetrahydroquinoline ferroptosis inhibitors for the treatment of acute kidney injury

    by Xie-Huang Sheng, Lin-Song Teng, Xiang-Shuai Meng, Yuan-Hao Song, Zhao-Hua Liu, Jing-Wen Sun, Deng-Feng Wu, Jian-Ping Ma, Lei Zhang

  • Open Access

    Ghrelin increases cis-platinum resistance and promotes aggressiveness of osteosarcoma by activating AKT and Wnt/β-catenin pathways

    by Menglin Cong, Shufeng Li, Yu Fu, Ting Wang, Huizhen Wei, Xiaojie Ma, Fangming Liu, XieHuang Sheng, Kehan Long, Haocheng Hou, et al.

    Osteosarcoma (OS) is the most common primary bone malignancy because of its extra high tendency of metastasis. In-depth research is needed to uncover the pathogenesis of patients with OS cells. We collected 74 tissue samples from patients with OS cells and measured the expression levels of ghrelin by immunohistochemistry. Ghrelin was added into OS cell lines in CCK8 assays, JC-1 staining and Western blot analysis were performed to explore its effect on the aggressiveness of OS cells and drug resistance. To determine its function, ghrelin was overexpressed or knocked down in OS cells and then detect cell proliferation in the xenograft mouse model and orthotopic model. Western blot analysis was performed to explore ghrelin-regulated signal pathways. In this work, we identified the relation between the level of ghrelin expression and poor prognosis of OS patients. As well as promoting proliferation, migration, and invation, ghrelin promotes the survival of OS in vitro as well as in vivo, and reduces the apoptosis of OS cells. What’s more, ghrelin increases the resistance of cis-platinum by changing mitochondrial function and decreases the expression of MDR-1. Above all, these results demonstrated ghrelin exerts tumorigenic and metastatic effects and may be a potential therapeutic target.


  • Regulation of macrophage polarization and pyroptosis by 4-methylcatechol alleviates collagen-induced arthritis via Nrf2/HO-1 and NF-κB/NLRP3 signaling pathways

    by Ying Zhendong, Chen Changjun, Hou Haocheng, Liu Qibin, Chen Dailing, Teng Linsong, Sun Xuecheng, Mouchun Gong, Zhang Lei


  • Open Access

    ZC3HAV1 facilitates STING activation and enhances inflammation

    by Danhui Qin, Hui Song, Caiwei Wang, Xiaojie Ma, Yu Fu, Chunyuan Zhao, Wei Zhao, Lei Zhang, Weifang Zhang

    Stimulator of interferon genes (STING) is vital in the cytosolic DNA-sensing process and critical for initiating the innate immune response, which has important functions in host defense and contributes to the pathogenesis of inflammatory diseases. Zinc finger CCCH-type antiviral protein 1 (ZC3HAV1) specifically binds the CpG dinucleotides in the viral RNAs of multiple viruses and promotes their degradation. ZAPS (ZC3HAV1 short isoform) is a potent stimulator of retinoid acid-inducible gene I (RIG-I) signaling during the antiviral response. However, how ZC3HAV1 controls STING signaling is unclear. Here, we show that ZC3HAV1 specifically potentiates STING activation by associating with STING to promote its oligomerization and translocation from the endoplasmic reticulum (ER) to the Golgi, which facilitates activation of IRF3 and NF-κB pathway. Accordingly, Zc3hav1 deficiency protects mice against herpes simplex virus-1 (HSV-1) infection- or 5,6-dimethylxanthenone-4-acetic acid (DMXAA)-induced inflammation in a STING-dependent manner. These results indicate that ZC3HAV1 is a key regulator of STING signaling, which suggests its possible use as a therapeutic target for STING-dependent inflammation.